KYTX
Kyverna Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.85
−0.68%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +6.3%
- EBIT
- +7.4%
- EPS
- +19.9%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- -13.9%
- EPS
- -2.5%
Three-year CAGR
- Revenue
- —
- EBITDA
- -27.0%
- EBIT
- -19.1%
- Net income
- -26.5%
- EPS
- -9.3%
- Free cash flow
- -32.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026